RefleXion Announces New Additions to Board of Directors and Appoints Audit Committee Chair
HAYWARD, Calif., May 27, 2021 – RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced the appointment of three external directors to its board of directors, Renee Ryan, Rana Al-Hallaq, Ph.D., and Alice Schroeder. Schroeder was also appointed chairperson of the Audit Committee. Al-Hallaq serves as a designee of Pfizer Inc.
“I am extremely pleased to welcome Renee, Rana and Alice to our board of directors as we transition to a commercial stage company,” said Todd Powell, president and CEO of RefleXion. “They also join RefleXion at the beginning of our clinical adoption in the U.S. as we have recently begun treating patients with conventional radiotherapy, the first step in our vision of delivering BgRT for late-stage cancer treatment. Each one brings impeccable credentials, including a wealth of financial, investment, health technology, and pharmaceutical industry experience. I look forward to their dedication, leadership and commitment to our vision.”
Ryan is CEO of Cala Health, a bioelectronic medicine company transforming the standard of care for chronic diseases, such as essential tremor, by merging innovations in neuroscience and technology. Under Ryan’s guidance, Cala Health is vertically integrating its commercial model to reshape the delivery of prescription therapies. Prior to Cala Health, she led the health technology investments for Johnson & Johnson Innovation on the West Coast and Asia Pacific for eight years. Previously, she was a healthcare investment banker at RW Baird, Jefferies and Goldman Sachs. Ryan holds a Bachelor of Arts degree from Georgetown University and an MBA from Columbia University.
Al-Hallaq is executive director and a partner at Pfizer Ventures, where she leverages her clinical and business development experience to assess, invest in, and manage equity investments. Beyond RefleXion, she has responsibility for Pfizer’s investments in Mitokinin, Autifony Therapeutics, Blade Therapeutics, Arkuda, Montis, Biograph55 and VectivBio, among others. Her experience at Pfizer also includes negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Prior to joining Pfizer, she held roles at Allergan in Clinical Development Psychiatry and Business Development. Al-Hallaq holds a Bachelor of Arts in Biology from Hamilton College and a Ph.D. in Neuroscience from Georgetown University.
Schroeder currently serves on the board of insurer/asset manager Prudential plc, where she chairs Responsibility and Sustainability and is a member of the Risk and Audit committees. She also chairs the Nominating and Governance committee and serves on the Audit and Compliance and Quality committees for Natus Medical. She is a former CPA, Wall Street analyst, banker and portfolio director, and has held positions with Morgan Stanley, CIBC Oppenheimer, PaineWebber and Ernst & Young. Schroeder was the former CEO of WebTuner, a tech startup that exited through sale to a strategic investment group. She holds a Bachelor of Arts in Business Administration and an MBA from the University of Texas at Austin.
RefleXion is a privately held commercial stage company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. BgRT incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
*The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to Investigational use.